Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The Knee Injury Cohort at the Kennedy (KICK) study has completed a significant milestone this week with the recruitment of all required participants – 150 individuals aged between 18 and 50 with recent knee injuries.

The Knee Injury Cohort at the Kennedy (KICK) study has completed a significant milestone this week with the recruitment of all required participants – 150 individuals aged between 18 and 50 with recent knee injuries.

After a joint injury, around 50% of people will go on to develop premature osteoarthritis. Chief investigator Dr Fiona Watt says: “Following the 150 participants in KICK over the next five years will help us to understand why a joint injury leads to osteoarthritis in some individuals, but not others. This will allow us to develop tests which identify those at greatest risk. We hope that this will ultimately enable us to intervene in key pathways following a joint injury to prevent this disabling condition”.

Other work in the Kennedy Institute has identified specific markers of inflammation following injury; KICK aims to determine whether it is possible to predict the development of osteoarthritis from this initial molecular response of the joint to the injury. The study also hopes to identify novel targets for preventing or treating early disease.

KICK is run at The Arthritis Research UK Centre for Osteoarthritis Pathogenesis, based in the Kennedy Institute of Rheumatology, at Oxford, and benefits from a range of collaborations, namely with Andrew Williams, leading UK sports knee surgeon working at Fortius Clinic, London. Commenting on the recent milestone, he said: “This is a great achievement. Understanding the key detrimental humoral 'players' that lead to osteoarthritis will open the possibility of providing therapies to prevent development of osteoarthritis after trauma which is especially prevalent in the young and increasingly so. The need for this is one of the most pressing goals in medicine today.”

KICK is funded by the Kennedy Trust for Rheumatology Research, with additional infrastructure support from Arthritis Research UK.

Similar stories

Communication at the crossroads of the immune system

In his inaugural article in the Proceedings of the National Academy of Sciences as an NAS member (elected 2021), Prof Mike Dustin and his research team have explained how messages are passed across the immunological synapse. The research could have implications for future vaccine development and immunotherapy treatments.

New drug offers hope for people with hand osteoarthritis

A new study, published in Science Translational Medicine by researchers at the University of Oxford has identified that Talarozole, a drug that is known to increase retinoic acid, was able to prevent osteoarthritis (OA) in disease models.

Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease

Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.

MRC funding awarded to Kennedy researchers

Two new projects led by Tal Arnon and Irina Udalova have been awarded Medical Research Council (MRC) funding.

Breakthrough in treatment for Dupuytren’s disease

Injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules is effective in reducing nodule hardness and nodule size.

New research suggests targeting blood vessels could be key to controlling fibrotic disease

By studying blood vessels at single cell resolution, Professor Jagdeep Nanchahal and colleagues found that in Dupuytren’s disease, a fibrotic disorder of the hand, the vasculature is key to orchestrating the development of human fibrosis.